La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Acticor Biotech SAS Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Gilles Avenard

Amministratore delegato

€361.7k

Compenso totale

Percentuale dello stipendio del CEO	74.0%
Mandato del CEO	3yrs
Proprietà del CEO	1.0%
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gilles Avenard rispetto agli utili di Acticor Biotech SAS?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	€362k	€268k	-€19m
Sep 30 2023	n/a	n/a	-€19m
Jun 30 2023	n/a	n/a	-€19m
Mar 31 2023	n/a	n/a	-€17m
Dec 31 2022	€751k	€250k	-€16m
Sep 30 2022	n/a	n/a	-€15m
Jun 30 2022	n/a	n/a	-€14m
Mar 31 2022	n/a	n/a	-€13m
Dec 31 2021	€1m	€173k	-€13m

Compensazione vs Mercato: La retribuzione totale di Gilles ($USD 403.73K ) è circa la media per le aziende di dimensioni simili nel mercato French ($USD 358.62K ).

Compensazione vs guadagni: La retribuzione di Gilles è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Gilles Avenard (73 yo)

3yrs

Mandato

€361,665

Compensazione

Dr. Gilles Avenard, M.D serves as Founder at Acticor Biotech SAS and has been its Chief Executive Officer since October 14, 2021 and was its Chairman until June 2021 and serves as its Director. He serves a...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gilles Avenard	Founder	3yrs	€361.67k	1.02% € 74.9k
Sophie Lebel-Binay	Deputy CEO	no data	€238.94k	Nessun dato
Yannick Pletan	Deputy CEO	6.8yrs	€279.91k	Nessun dato
Philippe Billiald	Scientific Founder	no data	Nessun dato	Nessun dato
Martine Jandrot-Perrus	Scientific Founder	no data	Nessun dato	Nessun dato
Eric Cohen	Chief Financial Officer	no data	Nessun dato	Nessun dato
Aymeric Humblot	Head of Finance & Administration	no data	Nessun dato	Nessun dato
Laurie Jullien	Head of Regulatory Affairs	no data	Nessun dato	Nessun dato
Kristell Lebozec	Head of Pharmaceutical Development	no data	Nessun dato	Nessun dato
Victoria Rutman	Head of Quality Assurance	no data	Nessun dato	Nessun dato
Elie Toledano	Head of Scientific Affairs & Business Intelligence	3.8yrs	Nessun dato	Nessun dato
Adeline Meilhoc	Head of Global Clinical Development	2.8yrs	Nessun dato	Nessun dato

3.4yrs

Durata media

71yo

Età media

Gestione esperta: Il team dirigenziale di ALACT è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gilles Avenard	Founder	no data	€361.67k	1.02% € 74.9k
Alain Munoz	Independent Chairman of the Board	3.3yrs	€80.00k	0.30% € 21.9k
Alain Parthoens	Director	1.9yrs	Nessun dato	Nessun dato
Catherine Boule	Director	no data	Nessun dato	Nessun dato
Rinaldo Del Bono	Director	3.8yrs	Nessun dato	3.14% € 231.3k
Patricia Zilliox	Independent Director	1.8yrs	€135.88k	Nessun dato
Guillaume Heynen	Observer	1.9yrs	Nessun dato	Nessun dato
James Stearns	Observer	2.8yrs	Nessun dato	Nessun dato
Jean-Pierre Cazenave	Independent Board Member	5.9yrs	€30.00k	0.0089% € 658.6
Leila Nicolas	Director	no data	Nessun dato	Nessun dato

2.8yrs

Durata media

70.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ALACT non è considerato esperto (durata media del mandato 2.6 anni), il che suggerisce un nuovo consiglio.

Acticor Biotech SAS Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024

Acticor Biotech SAS, Annual General Meeting, Jun 21, 2024

Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024

New major risk - Revenue and earnings growth

Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green Study

Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024

New minor risk - Financial data availability

Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024

Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million.

Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million.

The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack

Acticor Biotech SAS, Annual General Meeting, Jun 21, 2024

New major risk - Share price stability

Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal

Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million.

Forecast to breakeven in 2025

ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke

New minor risk - Share price stability

Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency (MHRA) Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

New minor risk - Profitability

Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director

Acticor Biotech SAS Provides an Update on the Progress of Its Clinical Programs with Glenzocimab

Acticor Biotech SAS Provides an Update on the US Regulatory Discussion with the FDA

Acticor Biotech Receives European Medicines Agency Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Acticor Biotech SAS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

Acticor Biotech SAS Receives Priority Medicines Status from the European Medicines Agency for Its Drug Candidate, Glenzocimab

Acticor Biotech SAS Announces Issuance of Patent in Europe for Glenzocimab, Its Innovative Product for the Treatment of Cardiovascular Emergencies

No longer forecast to breakeven

Less than half of directors are independent

Forecast to breakeven in 2023

Acticor Biotech Announces Positive Results from Its ACTIMIS PHASE 1b/2a Study in Patients With Acute Ischemic Stroke (AIS)

Acticor Biotech Announces Results of the Phase 2 Garden Study in Covid-19-Related Acute Respiratory Distress Syndrome

Less than half of directors are independent

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media